DrugPatentWatch Database Preview
Drugs in Development Information for PHA-793887
» See Plans and Pricing
What is the development status for investigational drug PHA-793887?
PHA-793887 is an investigational drug.
There have been 31 clinical trials for PHA-793887.
The most recent clinical trial was a Phase 3 trial, which was initiated on February 4th 2020.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Endocrine System Diseases, and Dwarfism, Pituitary. The leading clinical trial sponsors are National Cancer Institute (NCI), Nerviano Medical Sciences, and Pfizer.
There are twenty-one US patents protecting this investigational drug and one hundred and forty-eight international patents.
Summary for PHA-793887
| US Patents | 21 |
| International Patents | 148 |
| US Patent Applications | 87 |
| WIPO Patent Applications | 73 |
| Japanese Patent Applications | 22 |
| Clinical Trial Progress | Phase 3 (2020-02-04) |
| Vendors | 63 |
Recent Clinical Trials for PHA-793887
| Title | Sponsor | Phase |
|---|---|---|
| Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Pharvaris Netherlands B.V. | Phase 2 |
| Response to Oral Lansoprazole of Inorganic Pyrophosphate Levels in Patients With Grönblad-Stranberg Disease (Pseudoxanthoma Elasticum) | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | Phase 4 |
| The Benefit of Bermekimab in Patients With Systemic Sclerosis | Hellenic Institute for the Study of Sepsis | Phase 2 |
Clinical Trial Summary for PHA-793887
Top disease conditions for PHA-793887
Top clinical trial sponsors for PHA-793887
US Patents for PHA-793887
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| PHA-793887 | Start Trial | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (Boston, MA) | Start Trial |
| PHA-793887 | Start Trial | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Dana-Farber Cancer Institute, Inc. (Boston, MA) | Start Trial |
| PHA-793887 | Start Trial | Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 | Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) | Start Trial |
| PHA-793887 | Start Trial | Generation of muscle lineage cells and therapeutic uses thereof | GENEA BIOCELLS USA (HOLDINGS), INC. (San Diego, CA) | Start Trial |
| PHA-793887 | Start Trial | Maturation of hepatocyte-like cells derived from human pluripotent stem cells | Takara Bio Europe AB (Gothenburg, SE) | Start Trial |
| PHA-793887 | Start Trial | Inhibitors of cyclin-dependent kinase 7 (CDK7) | Syros Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PHA-793887
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| PHA-793887 | Australia | AU2014337044 | 2033-10-18 | Start Trial |
| PHA-793887 | Australia | AU2019200372 | 2033-10-18 | Start Trial |
| PHA-793887 | Canada | CA2927920 | 2033-10-18 | Start Trial |
| PHA-793887 | China | CN105849099 | 2033-10-18 | Start Trial |
| PHA-793887 | European Patent Office | EP3057956 | 2033-10-18 | Start Trial |
| PHA-793887 | Japan | JP2016533379 | 2033-10-18 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
